Wednesday, 19 February 2020

Struggling To Ride Ahead

05 July 2015 | Analysis | By BioSpectrum Bureau

Struggling To Ride Ahead

Mr Simin Zhang, chairman, Shenzen Neptunus Bioengineering

Mr Simin Zhang, chairman, Shenzen Neptunus Bioengineering

Singapore: 

SHENZHEN NEPTUNUS BIOENGINEERING, China
Revenue: $1533.1 mn
Chairman: Mr Simin Zhang
Business: Manufacturer of chemical pharmaceuticals, biopharmaceuticals, traditional Chinese medicines and healthcare products

Shenzhen Neptunus Bioengineering clocked revenue of $1533.1 million in 2014, rising around 22.63 percent from the previous year. However, the net income growth rate slipped to $3.7 million, declining by almost 79.67 percent from the previous year. The company later announced private placement of 306,122,448 shares of its common stock at a price of $1.6 per share, to raise gross proceeds of up to $489 million.

The company intended to use the proceeds for repayment of bank loans and supplement working capital.

Shenzhen Neptunus Bioengineering is pursuing a US Phase II clinical trial of Polydatin Injection, a class I innovative traditional Chinese that aids microcirculation of the blood. The vaccine is also being tested as a treatment for myocardial ischemia, cerebral ischemia, shock and other cardiovascular diseases.

In the first half of 2014, the company revealed revenue of $757 million, an increase of 24 percent from the previous earlier and the net profit was accounted to $8.54 million.

In 2014, Shenzhen Neptunus Bioengineering started the production of approved drugs including Tegafur, Gimeracil and Oteracil potassium Capsules for gastric cancer.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account